SEC Tracker
Get the app
ASMB · XBRL financial data

Assembly Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ASMB's year ends in late December)

In thousands of dollarsSep 30, 2023†Dec 31, 2023†Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers—————year only———year only——
Research and development10,82411,006*11,87916,25913,51514,280*14,85116,12516,58717,250*14,90014,917
General and administrative4,2248,708*4,6354,4774,2864,609*4,5094,5945,0855,420*4,6834,801
Total operating expenses15,04819,714*16,51420,73617,80118,889*19,36020,71921,67222,670*19,58319,718
Operating income (loss)(15,048)(12,551)*(10,729)(12,203)(10,956)(11,532)*(9,941)(11,093)(10,883)19,799*(11,370)(6,344)
Income tax expense (benefit)033*—4060(76)*—000*——
Net income (loss)(14,420)(10,962)*(9,077)(11,152)(9,613)(10,335)*(8,818)(10,198)(9,196)22,090*(9,079)(3,857)
Earnings per share, basic‡ USD per share(3.24)—(1.66)(1.98)(1.51)(1.58)*(1.17)(1.33)(0.72)—(0.54)(0.20)
Earnings per share, diluted‡ USD per share(3.24)—(1.66)(1.98)(1.51)(1.58)*(1.17)(1.33)(0.72)—(0.54)(0.20)
Weighted average shares, basic‡ thousands of shares4,379—5,4835,6436,3516,531*7,5067,65612,686—16,90018,854
Weighted average shares, diluted‡ thousands of shares4,379—5,4835,6436,3516,531*7,5067,65612,686—16,90018,854
  • ‡ Per-share figures and share counts are adjusted for the 1-for-12.004801920768308 stock split (February 2024); filings made before it reported them unadjusted.
  • † Share count changed about 1/12 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 12x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (ASMB's year ends in late December)

In thousands of dollarsSep 30, 2023†Dec 31, 2023†Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents26,65619,84118,74919,20828,45238,34423,41324,00622,53458,45031,12032,286
Marketable securities19,554110,40694,22790,01166,50273,73567,61550,974210,023189,656195,481288,075
Accounts receivable04343000——912974451822
Prepaid and other current assets3,4623,4974,1493,7123,2593,4244,4992,4873,3435,4695,5616,795
Total current assets49,672133,787117,168112,93198,213115,50395,52777,467236,812254,549232,613327,978
Property and equipment, net561385367349316284251219229221214315
Right-of-use asset8442,3392,0361,7311,4213,0692,9272,7822,6442,5082,3692,227
Total assets51,629136,823119,883115,323100,262119,16899,01780,780239,997257,590235,508330,832
Accounts payable7584617278011,3355858757431,6831,1711,1291,180
Accrued liabilities3,8865,7442,0513,5874,7656,8622,3023,4075,7287,7492,6643,342
Total current liabilities7,13239,22538,75341,27441,63547,80346,63147,29153,38048,78034,99723,445
Lease liability, non-current501,1227914511132,6282,4912,3512,2072,0591,9011,738
Total liabilities9,91595,72687,28280,64174,25985,80971,88462,68057,30250,83936,89825,183
Accumulated deficit(774,786)(785,748)(794,825)(805,977)(815,590)(825,925)(834,743)(844,941)(854,137)(832,047)(841,126)(844,983)
Total stockholders' equity41,71441,09732,60134,68226,00333,35927,13318,100182,695206,751198,610305,649
Total liabilities and equity51,629136,823119,883115,323100,262119,16899,01780,780239,997257,590235,508330,832
Common shares outstanding (cover page)‡ thousands of shares5,4744575,5136,3466,3567,5037,6387,67215,81715,86315,89320,361
  • ‡ Per-share figures and share counts are adjusted for the 1-for-12.004801920768308 stock split (February 2024); filings made before it reported them unadjusted.
  • † Share count changed about 1/12 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 12x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (ASMB's year ends in late December)

In thousands of dollarsSep 30, 2023†Dec 31, 2023†Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(14,420)(10,962)*(9,077)(11,152)(9,613)(10,335)*(8,818)(10,198)(9,196)22,090*(9,079)(3,857)
Stock-based compensation1,135*959*739833*797*751*712834*1,670*1,461*1,1162,416*
Depreciation and amortization116*84*3232*33*32*3332*32*32*2620*
Net cash from operating activities(13,848)*year only(18,364)(17,102)*(15,244)*(407)*(23,439)(16,758)*(15,133)*14,237*(22,097)(15,488)*
Purchases of property and equipment136*71*1414*0*0*00*42*24*190*
Net cash from investing activities18,881*(89,654)*17,2725,107*24,488*(6,696)*6,58616,994*(158,271)*21,223*(5,382)(92,081)*
Proceeds from issuing common stock0*0*00*0*2,030*1,9220*0*0*00*
Net cash from financing activities0*9,192*012,454*0*16,995*1,922357*171,932*456*149108,735*
Net change in cash5,033*(6,815)*(1,092)459*9,244*9,892*(14,931)593*(1,472)*35,916*(27,330)1,166*
  • † Share count changed about 1/12 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 12x in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Assembly Biosciences32,286not reported(15,488)*20.4M20.7 quarters 10-QJun 30, 2026
Milestone Pharmaceuticals169,728559(22,714)*124.5M7.5 quarters 10-QJun 30, 2026
DiaMedica Therapeutics5,129not reported(8,114)*53.9M5.4 quarters 10-QJun 30, 2026
Larimar Therapeutics92,687not reported(44,030)*103.9M3.5 quarters 10-QJun 30, 2026
Ironwood Pharmaceuticals79,127113,04158,276*165.2M— 10-QJun 30, 2026
Vaxart50,92927,1852,778*242.8M— 10-QJun 30, 2026
Achieve Life Sciences47,958not reported(10,777)*102.9M17.4 quarters 10-QJun 30, 2026
Fennec Pharmaceuticals41,24917,87450*35.1M— 10-QJun 30, 2026
Atossa Therapeutics26,094not reported(9,644)*10.0M2.7 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.